|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
FI903489A7
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
DE69233408T2
(de)
|
1991-12-02 |
2005-09-22 |
Cambridge Antibody Technology Ltd., Melbourn |
Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
US7138500B1
(en)
|
1993-05-07 |
2006-11-21 |
Immunex Corporation |
Antibodies to human 4-1BB
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
DE69624436T2
(de)
*
|
1995-04-08 |
2003-08-28 |
Lg Chemical Ltd., Seoul/Soul |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
|
US5994619A
(en)
|
1996-04-01 |
1999-11-30 |
University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus |
Production of chimeric bovine or porcine animals using cultured inner cell mass cells
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
US6974684B2
(en)
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US20030118588A1
(en)
|
1999-05-22 |
2003-06-26 |
Linda Diehl |
Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
KR100797667B1
(ko)
|
1999-10-04 |
2008-01-23 |
메디카고 인코포레이티드 |
외래 유전자의 전사를 조절하는 방법
|
|
JP4200627B2
(ja)
|
2000-03-01 |
2008-12-24 |
味の素株式会社 |
変異型チロシンリプレッサー遺伝子とその利用
|
|
NZ527302A
(en)
|
2001-01-05 |
2006-10-27 |
Abgenix Inc |
Antibodies to insulin-like growth factor I receptor
|
|
CA2436326C
(en)
|
2001-01-09 |
2012-08-14 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
|
|
JP4303105B2
(ja)
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
|
EA007232B1
(ru)
|
2001-08-17 |
2006-08-25 |
Коли Фармасьютикал Гмбх |
Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
JP2005519595A
(ja)
|
2002-03-01 |
2005-07-07 |
ダイアックス、コープ |
モジュラーリコンビナトリアルディスプレイライブラリー
|
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト4−1bbに対するヒト化抗体
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
CA2511910A1
(en)
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
JP4889493B2
(ja)
|
2003-05-14 |
2012-03-07 |
ドマンティス リミテッド |
ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
|
|
JP5087274B2
(ja)
|
2003-06-30 |
2012-12-05 |
ドマンティス リミテッド |
ポリペプチド
|
|
AR046094A1
(es)
*
|
2003-10-10 |
2005-11-23 |
Bristol Myers Squibb Co |
Anticuerpos completamente humanos contra 4-1bb humano
|
|
US7288638B2
(en)
*
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
US20070253961A1
(en)
|
2004-06-09 |
2007-11-01 |
Ulsan Industrial Education Foundation |
Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
|
|
EP1793857A4
(en)
|
2004-09-08 |
2008-09-03 |
Univ Ohio State Res Found |
COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES
|
|
CA2588157A1
(en)
|
2004-11-17 |
2006-05-26 |
Board Of Regents, The University Of Texas System |
Cancer immunotherapy incorporating p53
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
JP2008528010A
(ja)
|
2005-01-31 |
2008-07-31 |
アブリンクス ナームローゼ フェンノートシャップ |
重鎖抗体の可変ドメイン配列を作出する方法
|
|
WO2006088447A1
(en)
|
2005-02-15 |
2006-08-24 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
US20080194596A1
(en)
|
2005-06-03 |
2008-08-14 |
Frizer Inc. |
Therapeutic Combination Including a Selective Erbb2 Inhibitor
|
|
AU2006290433B2
(en)
|
2005-08-26 |
2012-06-07 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
CN1294146C
(zh)
|
2005-10-17 |
2007-01-10 |
山东大学 |
与t细胞表面共刺激分子cd137结合的多肽及其应用
|
|
AU2015201981A1
(en)
*
|
2005-10-21 |
2015-05-07 |
Genzyme Corporation |
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
|
WO2007062093A2
(en)
|
2005-11-22 |
2007-05-31 |
Incyte Corporation |
Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
|
|
KR101866623B1
(ko)
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 1가 항체 및 그의 제조 방법
|
|
MX2009005189A
(es)
*
|
2006-11-15 |
2009-06-30 |
Medarex Inc |
Anticuerpos humanos monoclonales para btla y metodos de uso.
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
JP5588865B2
(ja)
|
2007-07-31 |
2014-09-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトcd20に対するヒト抗体及びその使用方法
|
|
EP2591787A1
(en)
|
2007-08-13 |
2013-05-15 |
Pfizer Inc |
Combination motif immune stimulatory oligonucleotides with improved activity
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
AU2013202755B2
(en)
|
2007-08-22 |
2016-05-12 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
ES2336873B1
(es)
|
2007-11-07 |
2011-01-24 |
Proyecto De Biomedicina Cima, S.L. |
Composicion farmaceutica para el tratamiento de cancer.
|
|
SI2242771T1
(sl)
|
2007-12-14 |
2013-09-30 |
Bristol-Myers Squibb Company |
Vezane molekule k humanemu ox40 receptorju
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
WO2010132389A2
(en)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
NZ729044A
(en)
*
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
CN105247050B
(zh)
|
2013-03-14 |
2020-06-16 |
天演药业 |
用于文库构建、亲和力结合剂筛选和其表达的整合系统
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
EP3082839A4
(en)
|
2013-12-20 |
2017-08-09 |
National University of Singapore |
Differentiation therapy with cd137 ligand agonists
|
|
PT3134123T
(pt)
|
2014-02-21 |
2021-03-22 |
Nektar Therapeutics India Pvt Ltd |
Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
|
|
CN122399016A
(zh)
*
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
MX380176B
(es)
*
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
CN114014930A
(zh)
|
2015-02-13 |
2022-02-08 |
索伦托药业有限公司 |
结合ctla4的抗体治疗剂
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合cd137之抗體治療劑
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
BR112017024770A2
(pt)
*
|
2015-05-21 |
2018-07-31 |
Alligator Bioscience Ab |
polipeptídeos inovadores
|
|
US20160362469A1
(en)
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US10875926B2
(en)
*
|
2015-09-22 |
2020-12-29 |
Dingfu Biotarget Co., Ltd. |
Fully human antibody against human CD 137
|
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
AU2016370648B2
(en)
|
2015-12-15 |
2023-03-09 |
OncoC4, Inc. |
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
EP3394107A1
(en)
|
2015-12-22 |
2018-10-31 |
AbbVie Stemcentrx LLC |
Novel anti-tnfsf9 antibodies and methods of use
|
|
WO2017140826A1
(en)
|
2016-02-18 |
2017-08-24 |
Institut Gustave Roussy |
Methods and kits for predicting the sensitivity of a subject to immunotherapy
|
|
WO2017151940A2
(en)
|
2016-03-03 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
|
BR112019000512A2
(pt)
*
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业(苏州)有限公司 |
一种新的pd-1单克隆抗体
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
US10174122B2
(en)
|
2017-01-06 |
2019-01-08 |
Eutilex Co., Ltd. |
Anti-human 4-1BB antibodies and uses thereof
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
KR20180119135A
(ko)
|
2017-04-24 |
2018-11-01 |
주식회사 제넥신 |
4-1bbl 변이체 및 이를 포함하는 융합 단백질
|
|
MX2019012953A
(es)
|
2017-05-02 |
2020-02-12 |
Alligator Bioscience Ab |
Anticuerpo biespecifico contra ox40 y ctla-4.
|
|
IL270743B2
(en)
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
GB201712032D0
(en)
|
2017-07-26 |
2017-09-06 |
Bioinvent Int Ab |
Antibodies and uses thereof
|
|
AU2017428737B2
(en)
|
2017-08-21 |
2024-02-15 |
Adagene Inc. |
Dynamic human heavy chain antibody libraries
|
|
CN111511762B
(zh)
*
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
SG11202001549UA
(en)
|
2017-08-21 |
2020-03-30 |
Adagene Inc |
Dynamic human antibody light chain libraries
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
WO2019104716A1
(en)
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2020244574A1
(en)
|
2019-06-05 |
2020-12-10 |
Adagene Inc. |
Anti-cd137l antibodies and methods of using same
|
|
EP4149547A4
(en)
|
2020-05-13 |
2024-08-14 |
Adagene AG |
Compositions and methods for treating cancer
|
|
US20230242663A1
(en)
|
2020-06-23 |
2023-08-03 |
Adagene Pte. Ltd. |
Combination therapy comprising anti-cd137 antibodies
|
|
WO2022170619A1
(en)
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
WO2023168547A1
(en)
|
2022-03-07 |
2023-09-14 |
Adagene Pte. Ltd. |
Anti-cd137 antibodies and methods of making and using the same
|